weight and EC OG P er f Status)bX X X X X X X X X X X 12-Lead ECGaX X X X Vital Signs (T, HR, BP , RR)eX X X X X X X X X X X Concomitant Medication(s)/ Procedure(s) X X X X X X X X X X X X X Adverse Events (starting or worsening after IC)f X X X X X X X X X X X X X Specimens for Routine Laboratory Procedures Blood Hematology (complete blood count, differ ential, platelets)aX X X X X X X X X X X X X Chemistry (glucose, BUN, creat., Na, K, Cl, CO 2, Ca, Mg, protein, albumin, Tbili., AST, ALT, ALP, LDH)aX X X X X X X X X X X C hemistry cont. (Free T3, Free T4, TSH)aX X X X X X X X X X X C hemistr y cont. (Amy lase and lipase)aX X X X X X X X X X X Ur inaly sisa,cX X X X X X X C oagulation par ameter sa,dX Serum pregnancy test (Urine test only on Day 1)aX X X X X Specimens for Other Peripheral Blood Assays Blood for exosomal profiling aX X Blood for PaxGene RNA and DNAa,k Note: Discontinued per Amendment 9.1 XJXJX Blood (P BM C and plasma) for flow cy tometr y and biological assay sa,i,k Note: Discontinued per Amendment 9.1 Blood for humoral responses and other bi oma rkersa,k Note: Discontinued per Amendment 9.1 XJXJX Biopsy or FFPE slides for tumor microenvironmentgoptional post- treatment Ov er all Sur v iv al Progres s i on Free Survi va lLUD2014-012-VAC Study Flowchart (cont.) X XTreatment (each cycle = 4 weeks) Cycle 12 Long Term Follow-upTumor BiopsyEvery 6 months until 5 years post initiation of treatment33 37 39 41 Last Study Drug Dose + 91 ( ±7) days End of Study45Cycle 7 28J Tumor and Disease Assessments46Last Study Drug Dose +42 (±4) daysLast Study Drug Dose +28 ( ±4) days29 27Post Study Follow- upOn Study Follow-upf,K Cycle 10 Q8W starting 8 weeks after last disease assessment25 Study Week Sponsor: Ludwig Institute for Cancer Research. Protocol Number: LUD2014- 012-VAC.